Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.
locally advanced rectal cancer
patrolling monocytes
preoperative chemoradiotherapy
programmed cell death ligand 1 (PD-L1)
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
17
03
2022
received:
31
01
2022
accepted:
23
04
2022
pubmed:
4
5
2022
medline:
1
11
2022
entrez:
3
5
2022
Statut:
ppublish
Résumé
The clinical efficacy of chemoradiotherapy (CRT) is largely dependent on host immune status. The aim of this study was to identify possible markers expressed on circulating mononuclear cells to predict tumour response in patients with locally advanced rectal cancer (LARC). Peripheral blood samples were obtained from 47 patients diagnosed with LARC before and after CRT. The numbers of lymphocytes and monocyte subsets were analysed using flow cytometry. Based on clinical and pathological findings, patients were classified as high or low responders. Lymphocyte counts were markedly decreased after CRT. Total numbers of lymphocytes (p = 0.030) and CD4(+) T cells (p = 0.041) in post-CRT samples were significantly lower in low responders than in high responders. In contrast, monocyte counts were not reduced and the number of CD14 Programmed cell death ligand 1 (PD-L1) expression on patrolling monocytes suppresses cell-mediated immunity in patients receiving CRT which could be related to tumour response, and may be a useful biomarker for decision-making in the management of patients with LARC.
Identifiants
pubmed: 35502766
doi: 10.1111/codi.16167
pmc: PMC9790410
doi:
Substances chimiques
B7-H1 Antigen
0
Ligands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1149Informations de copyright
© 2022 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.
Références
Crit Care. 2017 Jul 14;21(1):186
pubmed: 28705256
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Lancet Oncol. 2014 Feb;15(2):184-90
pubmed: 24440473
Oncotarget. 2018 Apr 27;9(32):22368-22382
pubmed: 29854285
Cancer Immunol Immunother. 2017 Apr;66(4):523-535
pubmed: 28184968
Front Oncol. 2021 Oct 05;11:742728
pubmed: 34676170
J Immunol. 2012 Jul 15;189(2):558-66
pubmed: 22685313
J Immunol. 2020 Jan 1;204(1):192-198
pubmed: 31767784
Radiat Oncol. 2011 May 16;6:49
pubmed: 21575175
Colorectal Dis. 2022 Oct;24(10):1140-1149
pubmed: 35502766
Crit Care. 2016 May 09;20(1):124
pubmed: 27156867
Onco Targets Ther. 2017 Nov 22;10:5575-5583
pubmed: 29200872
Dis Colon Rectum. 2003 Jul;46(7):875-87
pubmed: 12847360
World J Surg Oncol. 2015 Feb 07;13:30
pubmed: 25890185
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Clin Oncol. 2008 Aug 1;26(22):3687-94
pubmed: 18669453
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
Br J Surg. 2019 Sep;106(10):1381-1392
pubmed: 31197828
Colorectal Dis. 2016 Mar;18(3):234-46
pubmed: 26531759
J Clin Invest. 2017 Aug 1;127(8):3039-3051
pubmed: 28691930
J Inflamm Res. 2021 Nov 10;14:5891-5899
pubmed: 34785927
Int J Mol Sci. 2017 Mar 07;18(3):
pubmed: 28272347
PLoS One. 2017 Aug 10;12(8):e0182883
pubmed: 28797063
Int J Oncol. 2017 Aug;51(2):393-404
pubmed: 28627602
Biomed Res Int. 2015;2015:921435
pubmed: 26504848
Immunity. 2003 Jul;19(1):71-82
pubmed: 12871640
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Medicine (Baltimore). 2017 Mar;96(13):e6487
pubmed: 28353591
Cancer Immunol Res. 2017 Sep;5(9):812-820
pubmed: 28811289
Viral Immunol. 2017 Apr;30(3):224-231
pubmed: 28005469
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567530
Oncoimmunology. 2020 Aug 28;9(1):1786888
pubmed: 32939320
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
J Clin Oncol. 2018 Jun 1;36(16):1611-1618
pubmed: 29437535
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
BMC Cancer. 2011 Feb 10;11:64
pubmed: 21306650
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780065
pubmed: 29909729
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Lancet Oncol. 2017 Jul;18(7):895-903
pubmed: 28551359
Blood. 2009 Jul 16;114(3):589-95
pubmed: 19349616
Nat Commun. 2020 Sep 24;11(1):4835
pubmed: 32973173
Science. 2007 Aug 3;317(5838):666-70
pubmed: 17673663
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):673-88
pubmed: 19480968
Oncology (Williston Park). 2012 Aug;26(8):730-5, 741
pubmed: 22957406
J Immunol. 2005 Jun 15;174(12):7516-23
pubmed: 15944250